Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bioengineered Artificial Mesenchymal Sheet (BAMS) is a cell-based therapeutic product designed for tissue regeneration and repair. It typically consists of mesenchymal stem cells (MSCs), often derived from adipose tissue, expanded on a biological matrix, such as fibrin-hyaluronic acid. The sheet format is engineered to preserve cell-to-cell contacts and the extracellular matrix, allowing for intact transplantation without enzymatic digestion. The therapeutic effect is primarily mediated by the MSCs' ability to secrete a wide array of paracrine factors, including growth factors and cytokines, which modulate inflammation, promote angiogenesis, stimulate tissue healing, and recruit host cells to the site of injury. This approach aims to improve cell retention and survival compared to traditional single-cell suspensions. BAMS is being investigated for various regenerative medicine applications, including the treatment of venous ulcers, corneal injuries, cartilage defects, bone regeneration, and skin wound healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bioengineered Artificial Mesenchymal Sheet.